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Abstract 
B-type natriuretic peptide is an important
prognostic marker in heart failure. However,
there are limited data for its value in non-car-
diac  intensive  care  unit  patients,  namely
regarding long-term prognosis. We investigat-
ed the long-term prognostic value of BNP in a
cohort  of  critically  ill  patients.  This  was  a
prospective and observational study, conduct-
ed  in  a  tertiary  university  hospital  20-bed
intensive care unit. We included 103 mechan-
ically-ventilated patients admitted for a non-
cardiac primary diagnosis; B-type natriuretic
peptide samples were obtained on admission.
A mean 14 (3-30) month follow up was avail-
able in 96.1% of patients who were discharged
from hospital. Mean age was 60.7±19.0 years
and  mean  APACHE  II  score  was  16.2±7.2.
APACHE  II  score  and  renal  dysfunction
increased with rising B-type natriuretic pep-
tide, with more than 60% of patients having B-
type natriuretic peptide levels of 100 pg/mL or
over; echocardiography-derived left ventricu-
lar ejection fraction was lower in patients with
higher B-type natriuretic peptide (P < 0.001).
Long-term survivors had lower median B-type
natriuretic  peptide  values  (117.5[2-1668]
pg/mL)  compared  with  intensive  care  unit
non-survivors  (191.0[5-4945]  pg/mL),
P<0.001. After adjustment to APACHE II score,
B-type natriuretic peptide levels of 300 pg/mL
or  over  were  independently  associated  with
long-term  mortality  (odds-ratio  4.1  [95%  CI
1.45-11.5], P=0.008). We conclude that in an
unselected  cohort  of  intensive  care  unit
patients, admission B-type natriuretic peptide
is frequently elevated, even without clinically
apparent acute heart disease, and is a strong
independent predictor of long-term mortality. 
Introduction
B-type  natriuretic  peptide  (BNP)  is  a  32
amino-acid  neurohormone  released  by  the
ventricles, secondary to the stretch of the car-
diac  myocytes.  It  has  powerful  physiological
effects on other organs, including the kidney
and vasculature, as it modulates myocardial
stretch and plasma volume through its diverse
actions as a diuretic, renin-angiotensin-aldos-
terone  system  antagonist,  vasodilator  and
inhibitor of sympathetic nerve activity.1 In the
emergency room (ER) or in the outpatient set-
ting, an increased plasma BNP level can help
to distinguish cardiac and non-cardiac causes
of dyspnea and is recommended as a screen-
ing tool in the latest heart failure (HF) guide-
lines.2 BNP is also an independent predictor of
cardiovascular events after an HF diagnosis,
either  acutely  decompensated3 or  in  stable
subjects.4 The mortality risk is proportional to
the magnitude of the BNP level on admission,
with an increase of the relative risk of death of
35% for every 100 pg.mL-1.5 Although the prog-
nostic  value  of  BNP  is  well  established  in
patients  with  HF,  acute  coronary  syndromes
(ACS)5 and  acute  pulmonary  embolism,6 its
role in the non-cardiac critically ill patient is
still under close scrutiny.7 Indeed, there are no
data  regarding  its  capability  of  predicting
long-term prognosis in this subset of patients.
We, therefore, studied the long-term prognos-
tic impact of BNP in an unselected cohort of
non-cardiac patients admitted to an intensive
care unit (ICU) of a tertiary care hospital. 
Materials and Methods 
Study protocol and patient popula-
tion 
We conducted a prospective, single-center,
observational  study  at  the  Department  of
Intensive  Care  Medicine  of  the  Coimbra
University Hospital between September 2007
and December 2007. Our unit is a 20-bed ter-
tiary care polyvalent medical and surgical ICU
that treats the entire spectrum of medical, sur-
gical and trauma patients. Adult patients were
eligible if they did not have an acute decom-
pensated  cardiac  condition  (ACS  and  acute
pulmonary  embolism  as  defined  by  current
guidelines,2,8,9 acute  decompensated  HF  or
acute arrhythmias as judged by the physician
responsible),  as  these  patients  are  usually
admitted by the cardiology department in a
dedicated 20-bed ICU. Patients with preexist-
ing coronary artery disease (CAD), history of
congestive HF and chronic supra-ventricular
arrhythmias, such as atrial fibrillation, were
included. If a patient required multiple admis-
sions to the ICU, data was collected only dur-
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ing the initial admission. Sepsis was defined
by  the  criteria  of  the  American  College  of
Chest  Physicians/Society  of  Critical  Care
Medicine  Consensus  Conference
Committee.10 The  study  was  conducted  in
accordance with applicable laws and regula-
tions, and ethical principles that have their
origin  in  the  Declaration  of  Helsinki.  The
study protocol was approved by the Coimbra
University.  The  hospital  review  board  and
patients gave their informed consent for the
data to be used in the analysis. 
Blood sampling 
For each patient, in addition to admission
routine  laboratory  assessment,  BNP  was
determined  using  a  commercially  available
assay  (ADVIA  Centaur® CP,  Siemens,
Germany).  Blood  in  EDTA  was  immediately
transported to our hospital central laboratory
where it was processed and analyzed within
one hour. The cut-off values for diagnosis of
decompensated  HF  have  been  established
elsewhere (BNP ≥100 pg/mL-1).2
Data collection
Baseline demographics and clinical history
were recorded in all patients. According to the
primary diagnosis on admission to the ICU,
the  reason  for  admission  was  classified  as
medical,  surgical  or  trauma.  Medical was
defined as a primary medical diagnosis (e.g.
pneumonia). Medical did not preclude a sec-
ondary cardiac disease, nor was a preexisting
cardiac  disease  a  priori  excluded.  Surgical
was defined in patients that had been subject-
ed to a surgical procedure which was the rea-
son for hospital admission. Trauma patients
were defined as patients admitted due to a
trauma. Disease severity was scored accord-
ing  to  the  Acute  Physiology  and  Chronic
Health Evaluation (APACHE II) system using
available data from the 24 h period at the time
of enrolment, with higher values indicating
more severe illness.11 Estimated glomerular
filtration  rate  (eGFR)  was  calculated  using
the Modification of Diet in Renal Disease for-
mula.12 On  the  basis  of  the  BNP  value  on
admission, we divided the population into two
pre-specified  groups  of  more  than  300
pg/mL–1 or less than 300 pg/mL–1, according to
literature data.13-15
Echocardiographic sub-study
An echocardiogram was performed within
the first 24 h of admission by the same expe-
rienced  dedicated  intensivist  operator,  the
examination being ordered at the discretion
of  the  primary  medical  team,  if  clinically
advised. Echocardiography was obtained in 43
patients using a Toshiba® (Nemio 30, Tokyo,
Japan)  sonographer  with  a  2.5  MHz  probe.
Measurements were made in M mode and left
ventricular ejection fraction was calculated by
biplanar Simpson’s method. Pulmonary artery
pressure was assessed by the measurement
of  peak  tricuspid  regurgitation  velocity  by
continuous Döppler plus estimated right atri-
al pressure from inferior vena cava measure-
ments. 
Study outcomes
ICU  survival  and  hospital  survival  were
recorded  in  all  patients,  whereas  long-term
survival  (median  14  (3-30)  months)  was
available in 96.1% of patients (99/103). Follow
up  was  obtained  by  personal  or  telephonic
interview and review of medical charts. 
Statistics 
Continuous  variables  are  expressed  as
mean  ±  SD  or  median  and  range  if  the
assumption of a normal distribution was vio-
lated,  using  the  Kolmogorov-Smirnov  test.
Categorical  variables  are  given  as  percent.
Comparisons  of  parameters  between  two
groups were made by unpaired Student’s t-
test or the Mann-Whitney U test, as appropri-
ate. APACHE II and BNP were evaluated for
their independent association with long-term
survival  by  logistic  regression.  Correlation
between BNP values and echocardiographic
variables  and  between  BNP  and  APACHE  II
score  were  performed  by  bivariate  analyses
with  Spearman’s  correlation.  Survival  was
analyzed by the Kaplan-Meier method. SPSS
12.0.1 (SPSS, Chicago, IL, USA) was used for
statistical  analyses.  P<0.05  was  considered
significant in all analyses. 
Results
Patients’ characteristics 
We enrolled 103 patients in the study, with
a  mean  age  of  60.7±19.0  years,  of  whom
60.2%  were  male.  All  patients  required
mechanical  ventilation,  and  the  mean  FiO2
was 57±18%. There was a wide range of dis-
ease severity, with a mean APACHE II score of
16.2±7.2.  Mean  BNP  serum  concentrations
were  markedly  elevated  (mean:  462.9
pg/mL–1; median: 159 pg/mL–1) over a broad
range  (2-4945  pg/mL–1).  Only  39.8%  (41  of
103) of the patients had values on admission
low enough to exclude decompensated HF as
per  current  guidelines  (<100  pg/mL–1)  and
almost one-third of the patients (31.1 %) had
a BNP of  300 pg/mL–1 or over. Most patients
were admitted for a medical illness (52.0%),
followed  by  surgical  and  trauma  in  similar
proportions (24.0%). Of the patients admitted
for medical illness, the most common diagno-
sis  was  pneumonia  (48.1%).  Most  trauma
patients had head trauma (62.5%). The most
common  diagnosis  in  surgical  patients  was
post-operatory  sepsis  (64.0%).  BNP  levels
were significantly lower in trauma patients
(39  [13.5-145.3]  pg/mL–1),  compared  with
medical  (188.5  [69.8-464.0]  pg/mL–1)  and
surgical  patients  (195.0  [75.5-566.3]
pg/mL–1), P=0.003. 
Outcomes 
There were 74 ICU survivors and 29 ICU
non-survivors (28.2%). A total of 62 patients
survived to discharge from hospital and 39.8%
died before discharge. At a median follow up
of 14 (3-30) months, there were 42 (42.4%)
survivors and 57 non-survivors (57.6%). 
BNP and clinical data 
We  divided  BNP  values  into  two  groups
(<300 pg/mL–1 and ≥ 300 pg/mL–1) to compare
clinical (Table 1) and laboratory characteris-
tics  (Table  2).  BNP  was  higher  in  older
patients (P<0.001), with increasing APACHE
II  scores  and  organ  failure.  As  expected,
patients with higher BNP had a higher preva-
lence  of  prior  CAD,  HF  and  hypertension.
Estimated GFR levels were lower in the group
with BNP 300 pg/mL–1 or over whereas CVP
levels  were  increased,  as  were  supportive
interventions,  including  vasopressor  usage.
Troponin  I  was  significantly  higher  in
patients  with  higher  BNP  levels  (Table  2).
Disease severity translated by the APACHE II
score,  correlated  well  with  BNP  (P=0.020,
r=0.228). 
BNP and echocardiographic data 
Echocardiographic data was available in 43
patients,  collected  within  the  first  24  h  of
admission by the same experienced operator.
BNP showed good correlation with left ven-
tricular  ejection  fraction  (LVEF)  (r=0.403,
P=0.007),  but  no  correlations  were  found
with other parameters (Table 3). 
BNP on admission and outcomes 
Patients with a BNP of 300 pg/mL–1 or over
had a long-term mortality rate of 80%, compared
with 48% in the group of patients with BNP less
than 300 pg/mL–1, yielding a hazard-ratio of  2.25
(1.3-3.8)  (log  rank  test  P=0.045)  (Figure  1).
Regarding  long-term  follow  up,  survivors  had
lower  admission  BNP  values  (median  117.5
[range  2-1668]  pg/mL–1)  than  non-survivors
(191.0  [5-4945]  pg/mL–1),  P=0.013.  ICU  sur-
vivors had significantly lower BNP values (BNP
117.5 [2 -4875] pg/mL–1) than ICU non-survivors
(328  [27-4945]  pg/mL–1),  P=0.003.  Likewise,
hospital survivors were characterized by signifi-
cantly lower BNP values (125 [2-4875] pg/mL–1)
vs non-survivors  (194  [18-4945]  pg/mL–1),
P=0.031. In a logistic multivariable regression
model,  values  of  BNP  over  300  pg/mL–1 were
independently associated with long-term mortal-
ity (OR 4.1 [95% CI 1.45-11.5], P=0.008), evenArticle
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after  adjustment  to  APACHE  II  score.
Discrimination was moderately better when BNP
was added to the APACHE II score, regarding
long-term survival (c-statistic = 0.727 [95% CI
0.628-0.812]  vs 0.666  [95%  CI  0.560-0.754],
P=0.114)  (Figure  2).  Using  the  European  HF
guidelines cut-off of 400 pg/mL–1 for decompen-
sated HF2, the results regarding long-term prog-
nostic ability and predictive power after adjust-
ment to APACHE II score are similar. 
Discussion
The present study shows that BNP is an inde-
pendent  predictor  of  long-term  survival  in  an
unselected cohort of critically ill patients admit-
ted to an ICU, even after adjustment to APACHE
II score. There are several reports regarding the
intra-hospital and short-term prognostic impact
of this biomarker.16 However, this study extends
those findings as it is the first to our knowledge
to demonstrate that BNP also has a strong long-
term prognostic impact. Elevated BNP levels on
admission were a frequent finding, with more
than 60% of patients having abnormal values
according to current recommendations,2 a simi-
lar proportion to other reports.17We also verified
a wide range of BNP values, as observed in pre-
vious studies with NT-pro-BNP.18-21
Causes of elevated BNP in critical
illness 
Although  myocardial  injury  is  one  of  the
major factors responsible for the elevation of
BNP,  other  important  mechanisms  include
renal failure and inflammation.16 As elevated
left ventricular wall tension is thought to be
the primary mechanism regulating the secre-
tion of BNP, elevated levels can either be due to
decompensated pre-existing cardiac disease or
Figure 1. Kaplan-Meier long-term survival
plots according to BNP level upon admis-
sion. 
Figure 2. Receiver operating characteristic
curve analysis for the entire cohort of crit-
ically  ill  patients.  The  area  under  the
receiver operating characteristic curve  for
prediction of long-term survival is 0.727
for the model with BNP and APACHE II
score (filled line). 
Table 1. Patients’ baseline characteristics.
BNP BNP
n = 103 patients  Total  <300 pg/mL–1 ≥300 p/mL–1 P value
Demographics 
Age (years) (mean, SD)  60.7±19.0  56.1±19.0  69.4±16.3  0.001 
Male (%)  60.2  62.0  56.3  0.583 
Prior history 
Coronary heart disease (%)  7.4  1.9  18.5  0.007 
Stroke/TIA (%)  13.4  14.4  11.1  0.668 
Peripheral artery disease (%)  7.3  5.5  11.1  0.355 
Arterial hypertension (%)  52.5  43.4  70.4  0.022 
Diabetes mellitus (%)  15.0  18.9  7.4  0.175 
Congestive heart failure (%)  33.0  22.1  56.3  0.001 
COPD (%)  22.0  14.5  37.0  0.021 
Vasopressor use on admission (%)  43.5  35.1  60.7  0.025 
ICU reason for admission 
Medical (%)  52.0  47.1  62.5 
Surgical (%)  24.0  23.5  23.5 
Trauma (%)  24.0  29.4  12.5  0.164 
Table 2. Patients’ baseline laboratory data and APACHE score.
BNP BNP
n = 103 patients  Total  <300 pg/mL–1 ≥300 pg/mL–1 P value
Hemoglobin (g/dL–1)  11.1±2.0  11.2±2.1  10.8±1.9  0.409 
Glycemia (mg/dL–1)  132.3±56.7  128.8±57.8  140.0 ±54.5  0.365 
eGFR (mL.min–1/m–2)  67.8±40.2  80.1±40.4  41.8±24.2  <0.001 
Sodium (mmol/L–1)  141.2±6.6  141.6±6.3  140.4±7.3  0.432 
Mean arterial pressure (mm Hg)  62.5±16.8  64.2±16.7  58.5±16.6  0.132 
Heart rate (beats per minute)  101.7±23.6  102.1±24.1  100.9±22.7  0.825 
Mean BNP (pg/dL–1)  462±857  99.4±80.5  1269.3±1196.2  <0.001 
Median BNP (pg/dL–1)  43 [159-410]  76 [28-161]  946 [430-1442]  <0.001 
Lactate (mg/dL–1)  1.5 [1.1-2.3]  1.4 [1.1-2.0]  1.9 [1.2-2.3]  0.104* 
Troponin I (µg/mL–1) (N=77)  0.08 [0.03-0.30]  0.04 [0.02-0.16]  0.24 [0.09-1.30]  <0.001* 
C-reactive protein (mg/dL–1)  15.0±12.3  14.9±12.6  15.2±11.8  0.928 
CVP (mmHg)  9±6  8±5  11±6  0.020 
Vasopressor on admission  43.5 %  35.1%  60.7%  0.025 
%APACHE II score 16.2±7.2 15.3±6.1 18.2±8.9 0.013
* Mann-Whitney test; CVP, central venous pressure. All laboratory measurements were taken within one hour of ICU admission. Lactates
were collected on the admission arterial blood gas analysis (radial or femoral artery). 
Table 3. Echocardiographic data on the first 24 h of admission. 
BNP BNP
n = 43  Total  <300  ≥300  P value  Spearman  P 
patients  pg/mL–1 pg/mL–1 r  value 
LVEF (%)  39.8±9.2   42.6±8.2  33.3±8.3  0.001  - 0.405  0.008 
TR (mmHg)  43.9±14.5  39.7±13.5  52.9±12.7  0.010  0.284  0.104 
LA (mm)  42.5±8.5   40.8±6.0  46.4±12.1  0.083  0.187  0.289 
LVEDD (mm)  58.0±8.4   57.6±4.1  58.9±14.5  0.666  0.042  0.818 
LVEF, left ventricular ejection fraction; TR, tricuspid regurgitant peak velocity gradient; LA, left atrium; LVEDD, left ventricular end-diastolic
diameter.Article
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to  acute  myocardial  injury.22 In  our  cohort,
higher BNP was significantly associated with
higher prevalence of CAD, HF and hyperten-
sion, identifying those patients with a higher
risk of mortality. Acute myocardial dysfunction
is also an important mechanism for the secre-
tion  of  natriuretic  peptides.23 In  our  study,
higher BNP levels correlated with higher CVP
and troponin I levels, and in the echocardio-
graphic  sub-analysis,  patients  with  higher
BNP values had also significantly lower LVEF
and  higher  Döppler-derived  indices  of  pul-
monary  artery  pressure.  However,  these
results may reflex a selection bias, as echocar-
diography was performed only in patients with
a clinical indication to do so. Other confound-
ing  factors,  such  as  interventions  that  alter
pre- and afterload, like vasopressors (used in
60%  of  patients),  volume  resuscitations  and
mechanical ventilation (in all patients), may
all have played a role in the secretion of BNP.
In view of the high prevalence of prior heart
disease, the association with lower LVEF, high-
er  troponins  and  higher  CVP,  the  elevated
natriuretic peptides levels in the critically ill
patients can potentially be of diagnostic and
therapeutic  importance.  Critical  illness  and
sepsis,  in  particular,  are  associated  with  an
intense inflammatory response, characterized
by markedly increased circulating pro-inflam-
matory cytokines, associated with elevated lev-
els of BNP in various reports.24 It is known that
upregulation of BNP can occur by pro-inflam-
matory cytokines (as IL-1 beta and TNF-alpha)
via p38 MAP kinase.25 The transcription of the
BNP  gene  can  also  be  activated  by
lipopolyssacharide and its promoter up-regu-
lated by IL-1.26 Interestingly, there was no sig-
nificant difference in C-reactive protein, as a
marker of unspecific inflammatory activation
and with prognostic power regarding heart dis-
ease27 between groups. Further investigation
is  warranted  to  clarify  the  relation  between
these two biomarkers. Heart dysfunction and
inflammation are not the only factors responsi-
ble for elevated BNP levels. Our results demon-
strate that eGFR is significantly decreased in
patients with BNP 300 pg/mL–1 or over, indicat-
ing another important additional mechanism
responsible for the elevation of BNP. Previous
studies have shown that BNP levels correlate
inversely with eGFR in chronic kidney disease
and that other factors besides impaired clear-
ance of the peptide, like neuro-hormonal acti-
vation and volume status of the patient, can
account for BNP elevation.28 Due to its unique
profile, BNP can translate a complex crosstalk
between the cardiac myocyte, the global vol-
ume  status  and  the  action  of  inflammatory
cytokines, eventually reflecting the presence of
a cardio-renal syndrome (CRS). CRS is defined
as a disorder of the heart and kidneys whereby
acute or chronic dysfunction in one organ may
induce  acute  or  chronic  dysfunction  in  the
other organ, as stated in a recent consensus
document.29 As biomarkers of integrated car-
dio-renal burden (a definition recently coined
by Yamashita et al.) natriuretic peptides may
be of use in defining the cardiac part of the
CRS30 and help in the diagnosis and prognosis
of its various forms, even in patients with var-
ious stages of renal insufficiency.31 A recent
report highlights the usefulness of BNP as a
marker for CRS type 4 in ICU patients.32 In the
context  of  the  critically  non-cardiac  patient
with simultaneous heart and kidney dysfunc-
tion, as in the patient with sepsis (CRS type 5),
the measurement of a load-independent bio-
marker  may  be  useful  to  assess  the  cardio-
renal burden. 
BNP and APACHE II and long-term
prognosis 
The assessment of prognosis in critically ill
patients  is  a  dynamic  and  very  challenging
process. Several tools have been developed and
the  most  widely  validated  is  the  APACHE  II
score,  a  multivariable11 and  rather  complex
system.17 However, in our analysis, BNP, as a
single measurement upon admission, seems
to provide complementary long-term prognos-
tic information to that obtained from APACHE
II,  with  a  dose-response  trend.  Our  results
regarding the discriminatory value of BNP are
similar to those reported by Meyer et al. in a
non-cardiac  population  regarding  short-term
survival33 and extend to long-term prognosis
the results of several published observations
regarding intra-hospital BNP prognostic value.
They can be of particular value in the emer-
gency  unit,  where  rapid  decision-making  is
required for an unselected cohort of critically
ill patients.23 Although the treatment of a post-
ACS cohort with normal LVEF but elevated BNP
levels  with  angiotensin-converting  enzyme
inhibitors (ACEi), direct  renin inhibitors or
both did not impact on survival in the recently
published AVANT GARDE-TIMI 43 trial,21 grow-
ing evidence indicates that BNP-guided treat-
ment of HF may reduce mortality, especially in
younger patients.34 The ability of BNP to inte-
grate  several  surrogates  of  poor  prognosis,
such  as  advanced  age,  renal  impairment,
inflammation and pre-existing LV systolic or
diastolic dysfunction, converts it into a weight-
ed sum of different risk markers, meaning its
short  and  long-term  prognostic  power  is
derived from this lack of specificity.5 The pres-
ent study, extending the impact of an elevated
admission BNP on long-term prognosis, high-
lights the importance of early detection and
careful monitoring of patients with elevation
of this biomarker, both during hospitalization
and particularly after discharge. Patients with
higher BNP levels on admission may be candi-
dates  for  an  early  echocardiogram  to  detect
subclinical heart disease, since clinical signs
of  HF  may  be  difficult  to  identify  in  ICU
patients.  An  early  echocardiogram  may  also
indicate  cardio-renal  disease,  prompting  the
initiation  of  long-term  protective  therapies
after  ICU  discharge,  such  as  ACEi  or  beta-
blockers, as many of the patients die in the
first 100 to 150 days after discharge. 
Study limitations 
The relatively small sample size in our study
may have limited the associations between the
different variables and due to technical limita-
tions, it was not possible to collect echocardio-
graphic data in all patients. We only analyzed
admission BNP, but it is known that there are
significant changes in BNP and renal function
in the first days after admission.13 However,
this has not compromised its important prog-
nostic power. Although some of the patients
had  cardiovascular  comorbidities  that  may
have had a significant impact on BNP levels
(patients  with  pre-existing  CAD,  history  of
congestive  HF  and  chronic  supra-ventricular
arrhythmias,  such  as  atrial  fibrillation),  our
study population reflects a non-selected cohort
that may be found in a polyvalent ICU, high-
lighting the important role of BNP in signaling
the cardio-renal interactions in those patients.
Moreover, we used similar inclusion and exclu-
sion  criteria  to  those  found  in  other  stud-
ies.17,33
Invasive hemodynamic variables other than
CVP  were  not  collected,  as  recent  evidence
does  not  support  the  routine  placement  of
indwelling  pulmonary  catheters;35 moreover,
previous studies had not found a good correla-
tion between natriuretic peptides and left ven-
tricular filling pressures in ICU patients.23 The
impact  of  cardio-renal  protective  therapies,
instituted after discharge, has not been taken
into account. Areas under curve (AUC) for iso-
lated APACHE II score and BNP regarding long-
term prognosis were rather low in our popula-
tion (<0.7). Nevertheless, APACHE II score will
continue to be be used clinically in this popu-
lation and as a consequence of these low AUC,
the use of a single variable might be insuffi-
cient. With the addition of BNP to APACHE II
score, the AUC yields a value of 0.73 that is
acceptable for clinical decision-making.
Conclusions
The present study demonstrates that in an
unselected cohort of ICU patients, admission
BNP levels are frequently elevated, even with-
out  clinically  apparent  acute  heart  disease.Article
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BNP levels correlated well with the severity of
disease and had long-term independent prog-
nostic  impact  on  mortality,  with  an  additive
effect to the APACHE II risk score. More studies
are warranted in larger cohorts to determine if
this simple, widely available and non-invasive
test is useful to identify patients who can bene-
fit from strategies aimed to suppress the cardio-
renal burden on long-term prognosis. 
This study was presented in part at the 21st
Congress of the European Society of Intensive
Care Medicine (2008), Lisbon, Portugal. 
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